デフォルト表紙
市場調査レポート
商品コード
1404814

医薬品原薬の市場規模、シェア、動向分析レポート:合成タイプ別、メーカー別、タイプ別、用途別、医薬品タイプ別、地域別、セグメント予測、2024-2030年

Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Type Of Synthesis (Biotech, Synthetic), By Type Of Manufacturer (Captive, Merchant), By Type, By Application, By Type Of Drug, By Region, & Segment Forecasts, 2024-2030

出版日: | 発行: Grand View Research | ページ情報: 英文 191 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
医薬品原薬の市場規模、シェア、動向分析レポート:合成タイプ別、メーカー別、タイプ別、用途別、医薬品タイプ別、地域別、セグメント予測、2024-2030年
出版日: 2023年11月29日
発行: Grand View Research
ページ情報: 英文 191 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

医薬品原薬市場の成長と動向:

世界の医薬品原薬市場規模は、2024年から2030年までCAGR5.75%で拡大し、2030年には3,529億8,000万米ドルに達すると予測されます。

市場を牽引するのは、バイオ医薬品分野の成長、原薬(API)製造の進歩、高齢者人口の増加です。

キャプティブAPI分野の成長は、企業がAPIを自社生産するための課題解決や新しい化学的方法の開発に投資することによって推進されます。これはコストと汚染リスクの削減に役立ちます。人工知能とタンパク質合成は、プロセスの制御性を高め、より迅速な開発を促進すると期待されています。

心血管疾患などの慢性疾患やライフスタイルに基づく疾患の有病率の上昇は、APIの需要を加速させています。例えば、2020年の米国薬剤師によると、成人の47%が心血管疾患発症をサポートする危険因子を少なくとも1つ持っています。心血管疾患は、世界の公衆衛生上の重大な負担の一つであり、この分野における原薬の広範な研究開発を推進しています。

原薬市場は、COVID-19のパンデミックから好影響を受け、COVID-19の治療需要を満たすために、各国や主要企業が大量の成分を生産しています。大流行の結果、製薬会社はより多くの患者集団に焦点を当てるよう戦略を変更しました。コロナウイルスを治療するため、例えば米国はHCQをインドから輸入するよう要請しました。このウイルスはカナダの医薬品供給システムにも影響を与え、患者に合併症を引き起こす可能性があります。ジェネリック医薬品の重要性の高まり、バイオ医薬品消費の増加、医薬品製造のための研究開発活動の拡大が、市場成長の主な促進要因です。しかし、市場の拡大は、いくつかの国における不利な薬価規制と高い製造コストによって阻害される可能性が高いです。

インドのような新興国は、地政学的な状況により、中国のようなAPI市場の支配的な国々よりも市場で選好されています。さらに、インドには高品質の原料や製品、大規模な労働力、広大な流通網、「Make in India」プログラムによる政府補助金があります。

アンメット・メディカル・ニーズに対応するため、企業は共同で新規治療法を開発しています。これによって、企業は自社のリソースを製品の開発に役立て、サプライチェーンを強化することができます。2021年11月、Merck &Co Inc.は、Acceleron Pharmaを買収したと発表しました。この買収は、Merck &Coの心血管ポートフォリオとパイプラインの拡大に役立つと思われます。

原薬市場レポートハイライト

  • 新薬開発のための研究開発活動の活発化と政府の積極的な取り組みにより、2023年には革新的APIが62.0%の最大シェアを占めました。
  • Captive APIセグメントは2023年に51.03%の最大シェアを占めました。
  • 合成APIセグメントは、2023年に70.66%の最大収益シェアで市場を独占したが、これは原料の入手可能性が高く、これらの分子の合成プロトコールが容易なためです。
  • 北米は2023年に38.26%の最大収益シェアを占め、予測期間中もリードを維持すると予測されています。これは、他の生活習慣病とともにがんの疫学が上昇しているため、研究開発活動が促進され、市場の成長を後押ししているためです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
  • 市場促進要因
    • 高齢者人口の増加
    • 院内感染、遺伝性疾患、心血管疾患、神経疾患などの標的疾患の有病率の上昇
    • がん治療における標的療法アプローチへの関心の高まり
    • APIのアウトソーシングを求める声が高まる
  • 市場抑制要因分析
    • 多額の設備投資と生産コスト
    • 原薬に関する厳しい安全性と取り扱い規制
  • 事業環境分析
    • SWOT分析;要因別(政治・法律、経済・技術)
    • ポーターのファイブフォース分析
    • COVID-19感染症の影響分析

第4章 合成タイプビジネス分析

  • 医薬品原薬市場:合成タイプ変動分析
  • 生物API
  • 合成API

第5章 メーカータイプビジネス分析

  • 医薬品原薬市場:メーカータイプの変動分析
  • キャプティブAPI
  • マーシャントAPI

第6章 タイプビジネス分析

  • 医薬品原薬市場:タイプの変動分析
  • 汎用 API
  • 革新的なAPI

第7章 用途ビジネス分析

  • 医薬品原薬市場:用途変動分析
  • 心血管疾患
  • 腫瘍学
  • 中枢神経系と神経学
  • 整形外科
  • 内分泌学
  • 呼吸器科
  • 消化器科
  • 腎臓学
  • 眼科
  • その他

第8章 医薬品タイプビジネス分析

  • 医薬品原薬市場:薬物変動分析の種類
  • 処方箋
  • OCT

第9章 地域ビジネス分析

  • 地域別の医薬品原薬市場シェア、2023年および2030年
  • 北米
    • 北米の医薬品原薬市場、2018~2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州の医薬品原薬市場、2018~2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • アジア太平洋地域の医薬品原薬市場、2018~2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカの医薬品原薬市場、2018~2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • MEA医薬品原薬市場、2018~2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第10章 競合情勢

  • 参入企業の概要
  • 財務実績
  • 参入企業
    • マーケットリーダー
    • 医薬品原薬市場シェア分析、2023年
    • 企業プロファイル
    • 戦略マッピング
図表

List of Tables

  • Table 1 List of Tables
  • Table 2 Global Active Pharmaceutical Ingredients Market, By Region, 2018 - 2030 (USD Billion)
  • Table 3 Global Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 4 Global Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 5 Global Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 6 Global Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 7 Global Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 8 North America Active Pharmaceutical Ingredients Market, By Country, 2018 - 2030 (USD Billion)
  • Table 9 North America Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 10 North America Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 11 North America Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 12 North America Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 13 North America Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 14 U.S. Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 15 U.S. Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 16 U.S. Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 17 U.S. Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 18 U.S. Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 19 Canada Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 20 Canada Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 21 Canada Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 22 Canada Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 23 Canada Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 24 Europe Active Pharmaceutical Ingredients Market, By Country, 2018 - 2030 (USD Billion)
  • Table 25 Europe Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 26 Europe Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 27 Europe Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 28 Europe Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 29 Europe Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 30 UK Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 31 UK Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 32 UK Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 33 UK Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 34 UK Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 35 Germany Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 36 Germany Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 37 Germany Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 38 Germany Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 39 Germany Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 40 France Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 41 France Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 42 France Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 43 France Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 44 France Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 45 Italy Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 46 Italy Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 47 Italy Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 48 Italy Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 49 Italy Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 50 Spain Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 51 Spain Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 52 Spain Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 53 Spain Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 54 Spain Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 55 Denmark Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 56 Denmark Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 57 Denmark Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 58 Denmark Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 59 Denmark Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 60 Sweden Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 61 Sweden Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 62 Sweden Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 63 Sweden Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 64 Sweden Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 65 Norway Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 66 Norway Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 67 Norway Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 68 Norway Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 69 Norway Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 70 Asia Pacific Active Pharmaceutical Ingredients Market, By Country, 2018 - 2030 (USD Billion)
  • Table 71 Asia Pacific Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 72 Asia Pacific Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 73 Asia Pacific Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 74 Asia Pacific Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 75 Asia Pacific Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 76 Japan Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 77 Japan Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 78 Japan Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 79 Japan Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 80 Japan Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 81 China Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 82 China Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 83 China Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 84 China Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 85 China Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 86 India Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 87 India Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 88 India Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 89 India Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 90 India Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 91 Australia Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 92 Australia Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 93 Australia Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 94 Australia Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 95 Australia Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 96 South Korea Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 97 South Korea Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 98 South Korea Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 99 South Korea Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 100 South Korea Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 101 Thailand Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 102 Thailand Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 103 Thailand Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 104 Thailand Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 105 Thailand Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 106 Latin America Active Pharmaceutical Ingredients Market, By Country, 2018 - 2030 (USD Billion)
  • Table 107 Latin America Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 108 Latin America Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 109 Latin America Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 110 Latin America Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 111 Latin America Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 112 Brazil Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 113 Brazil Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 114 Brazil Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 115 Brazil Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 116 Brazil Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 117 Mexico Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 118 Mexico Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 119 Mexico Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 120 Mexico Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 121 Mexico Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 122 Argentina Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 123 Argentina Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 124 Argentina Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 125 Argentina Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 126 Argentina Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 127 Middle East & Africa Active Pharmaceutical Ingredients Market, By Country, 2018 - 2030 (USD Billion)
  • Table 128 Middle East & Africa Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 129 Middle East & Africa Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 130 Middle East & Africa Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 131 Middle East & Africa Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 132 Middle East & Africa Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 133 South Africa Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 134 South Africa Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 135 South Africa Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 136 South Africa Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 137 South Africa Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 138 Saudi Arabia Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 139 Saudi Arabia Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 140 Saudi Arabia Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 141 Saudi Arabia Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 142 Saudi Arabia Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 143 UAE Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 144 UAE Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 145 UAE Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 146 UAE Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 147 UAE Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)
  • Table 148 Kuwait Active Pharmaceutical Ingredients Market, By Type of Synthesis, 2018 - 2030 (USD Billion)
  • Table 149 Kuwait Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 - 2030 (USD Billion)
  • Table 150 Kuwait Active Pharmaceutical Ingredients Market, By Type, 2018 - 2030 (USD Billion)
  • Table 151 Kuwait Active Pharmaceutical Ingredients Market, By Application, 2018 - 2030 (USD Billion)
  • Table 152 Kuwait Active Pharmaceutical Ingredients Market, By Type of Drug, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Active pharmaceutical ingredients market segmentation
  • Fig. 8 Market driver relevance analysis (Current & future impact)
  • Fig. 9 Market restraint relevance analysis (Current & future impact)
  • Fig. 10 Market challenge relevance analysis (Current & future impact)
  • Fig. 11 Penetration & growth prospect mapping
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Market penetration vs growth prospect mapping
  • Fig. 15 Active pharmaceutical ingredients market: Type of synthesis movement analysis
  • Fig. 16 Biotech APIs market, 2018 - 2030 (USD Billion)
  • Fig. 17 Synthetic APIs market, 2018 - 2030 (USD Billion)
  • Fig. 18 Active pharmaceutical ingredients market: Type of manufacturer movement analysis
  • Fig. 19 Captive APIs market, 2018 - 2030 (USD Billion)
  • Fig. 20 Merchant APIs market, 2018 - 2030 (USD Billion)
  • Fig. 21 Active pharmaceutical ingredients market: Type movement analysis
  • Fig. 22 Generic APIs market, 2018 - 2030 (USD Billion)
  • Fig. 23 Innovative APIs market, 2018 - 2030 (USD Billion)
  • Fig. 24 Active pharmaceutical ingredients market: Application movement analysis
  • Fig. 25 Cardiovascular diseases market, 2018 - 2030 (USD Billion)
  • Fig. 26 Oncology market, 2018 - 2030 (USD Billion)
  • Fig. 27 CNS and Neurology market, 2018 - 2030 (USD Billion)
  • Fig. 28 Orthopaedic market, 2018 - 2030 (USD Billion)
  • Fig. 29 Endocrinology market, 2018 - 2030 (USD Billion)
  • Fig. 30 Pulmonology market, 2018 - 2030 (USD Billion)
  • Fig. 31 Gastroenterology market, 2018 - 2030 (USD Billion)
  • Fig. 32 Nephrology market, 2018 - 2030 (USD Billion)
  • Fig. 33 Ophthalmology market, 2018 - 2030 (USD Billion)
  • Fig. 34 Others market, 2018 - 2030 (USD Billion)
  • Fig. 35 Active pharmaceutical ingredients market: Type of drug movement analysis
  • Fig. 36 Prescription market, 2018 - 2030 (USD Billion)
  • Fig. 37 OTC market, 2018 - 2030 (USD Billion)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Regional outlook, 2018 & 2030
  • Fig. 40 North America active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 41 U.S. active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 42 Canada active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 43 Europe active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 44 UK active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 45 Germany active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 46 Italy active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 47 Spain active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 48 France active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 49 Denmark active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 50 Sweden active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 51 Norway active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 52 Asia Pacific active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 53 Japan active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 54 China active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 55 India active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 56 Australia active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 57 South Korea active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 58 Thailand active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 59 Latin America active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 60 Brazil active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 61 Mexico active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 62 Argentina active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 63 MEA active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 64 South Africa active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 65 Saudi Arabia active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 66 UAE active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • Fig. 67 Kuwait active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
目次
Product Code: GVR-1-68038-348-5

Active Pharmaceutical Ingredients Market Growth & Trends:

The global active pharmaceutical ingredients market size is expected to reach USD 352.98 billion by 2030, expanding at a compound annual growth rate (CAGR) of 5.75% from 2024 to 2030. The market is driven by the growth of the biopharmaceutical sector, advancements in active pharmaceutical Ingredients (API) manufacturing, and an increase in the geriatric population.

The growth of the captive API segment is propelled by companies investing in solving challenges and developing new chemical ways for the production of APIs in-house. This aids in reducing costs and the risk of contamination. Artificial intelligence and protein synthesis are expected to facilitate faster development with greater control over the process.

The rising prevalence of chronic and lifestyle-based conditions, such as cardiovascular diseases, is accelerating the demand for API. For instance, as per U.S. Pharmacist in 2020, 47% of adults have at least one risk factor that supports cardiovascular disease development. Cardiovascular diseases are one of the global, critical public health burdens driving extensive R&D for APIs in the field.

The active pharmaceutical Ingredients market was positively influenced by the COVID-19 pandemic, as countries and significant players produce large quantities of components to meet the demand for the treatment of COVID-19. As a result of the outbreak, drug companies have changed the companies' strategies to focus on a larger patient population. To treat coronavirus, the U.S., for example, requested that HCQ be imported from India. The virus has also impacted Canada's medicine supply system, potentially causing complications for patients. The increasing importance of generics, rise in consumption of biopharmaceuticals, and expanding drug research and development activities for drug manufacturing are the primary drivers driving the growth of the market. However, the market's expansion is likely to be hampered by unfavorable drug price control regimes in several countries and high manufacturing costs.

Developing nations like India are receiving an increased preference in the market over dominant API market countries, like China, owing to geopolitical situations. Furthermore, India has quality raw materials and products, a large workforce, a vast distribution network, and government subsidies through the "Make in India" program.

To address unmet medical needs, companies are collaborating to develop novel treatments. This allows firms to use their resources to aid in the development of products and enhance the supply chain. In November 2021, Merck & Co Inc. announced that it has acquired Acceleron Pharma, this acquisition would help Merck & Co to expand their cardiovascular portfolio and pipeline.

Active Pharmaceutical Ingredients Market Report Highlights:

  • Innovative APIs held the largest share of 62.0% in 2023, owing to increasing research and development activities for novel drug development and positive government initiatives
  • Captive APIs segment held the largest market share of 51.03% in 2023
  • The synthetic API segment dominated the market with the largest revenue share of 70.66% in 2023, owing to the higher availability of raw materials and easier protocols for the synthesis of these molecules
  • North America accounted for the largest revenue share of 38.26% in 2023 and is expected to maintain its lead over the forecast period. This is attributed to the rising epidemiology of cancer, along with other lifestyle-induced diseases, thus encouraging the R&D activities, thereby boosting the market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Increasing geriatric population
    • 3.4.2. Rising prevalence of target diseases such as hospital-acquired infections, genetic, cardiovascular, and neurological diseases
    • 3.4.3. Increasing preference for targeted therapy approach in cancer treatment
    • 3.4.4. Increasing preference for outsourcing APIs
  • 3.5. Market Restraint Analysis
    • 3.5.1. High capital investments and production cost
    • 3.5.2. Stringent Safety and handling regulations regarding APIs
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Type of Synthesis Business Analysis

  • 4.1. Active Pharmaceutical Ingredients Market: Type of Synthesis Movement Analysis
  • 4.2. Biotic APIs
    • 4.2.1. Biotic APIs Market, 2018 - 2030 (USD Billion)
      • 4.2.1.1. Biotech APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)
      • 4.2.1.2. Generic APIs
      • 4.2.1.2.1. Generic APIs Market, 2018 - 2030 (USD Billion)
      • 4.2.1.3. Innovative APIs
      • 4.2.1.3.1. Innovative APIs Market, 2018 - 2030 (USD Billion)
      • 4.2.1.4. Biotech APIs Market, By Product (Revenue, USD Billion, 2018 - 2030)
      • 4.2.1.5. Monoclonal Antibodies
      • 4.2.1.5.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Billion)
      • 4.2.1.6. Hormones
      • 4.2.1.6.1. Hormones Market, 2018 - 2030 (USD Billion)
      • 4.2.1.7. Cytokines
      • 4.2.1.7.1. Cytokines Market, 2018 - 2030 (USD Billion)
      • 4.2.1.8. Recombinant Proteins
      • 4.2.1.8.1. Recombinant Proteins Market, 2018 - 2030 (USD Billion)
      • 4.2.1.9. Therapeutic Enzymes
      • 4.2.1.9.1. Therapeutic Enzymes Market, 2018 - 2030 (USD Billion)
      • 4.2.1.10. Vaccines
      • 4.2.1.10.1. Vaccines Market, 2018 - 2030 (USD Billion)
      • 4.2.1.11. Blood Factors
      • 4.2.1.11.1. Blood Factors Market, 2018 - 2030 (USD Billion)
  • 4.3. Synthetic APIs
    • 4.3.1. Synthetic APIs Market, 2018 - 2030 (USD Billion)
      • 4.3.1.1. Synthetic APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)
      • 4.3.1.2. Generic APIs
      • 4.3.1.2.1. Generic APIs Market, 2018 - 2030 (USD Billion)
      • 4.3.1.3. Innovative APIs
      • 4.3.1.3.1. Innovative APIs Market, 2018 - 2030 (USD Billion)

Chapter 5. Type of Manufacturer Business Analysis

  • 5.1. Active Pharmaceutical Ingredients Market: Type of Manufacturer Movement Analysis
  • 5.2. Captive APIs
    • 5.2.1. Captive APIs Market, 2018 - 2030 (USD Billion)
  • 5.3. Merchant APIs
    • 5.3.1. Merchant APIs Market, 2018 - 2030 (USD Billion)

Chapter 6. Type Business Analysis

  • 6.1. Active Pharmaceutical Ingredients Market: Type Movement Analysis
  • 6.2. Generic APIs
    • 6.2.1. Generic APIs Market, 2018 - 2030 (USD Billion)
  • 6.3. Innovative APIs
    • 6.3.1. Innovative APIs Market, 2018 - 2030 (USD Billion)

Chapter 7. Application Business Analysis

  • 7.1. Active Pharmaceutical Ingredients Market: Application Movement Analysis
  • 7.2. Cardiovascular Diseases
    • 7.2.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Billion)
  • 7.3. Oncology
    • 7.3.1. Innovative APIs Oncology Market, 2018 - 2030 (USD Billion)
  • 7.4. CNS and Neurology
    • 7.4.1. CNS and Neurology Market, 2018 - 2030 (USD Billion)
  • 7.5. Orthopedic
    • 7.5.1. Orthopedic Market, 2018 - 2030 (USD Billion)
  • 7.6. Endocrinology
    • 7.6.1. Endocrinology Market, 2018 - 2030 (USD Billion)
  • 7.7. Pulmonology
    • 7.7.1. Pulmonology Market, 2018 - 2030 (USD Billion)
  • 7.8. Gastroenterology
    • 7.8.1. Gastroenterology Market, 2018 - 2030 (USD Billion)
  • 7.9. Nephrology
    • 7.9.1. Nephrology Market, 2018 - 2030 (USD Billion)
  • 7.10. Ophthalmology
    • 7.10.1. Ophthalmology Market, 2018 - 2030 (USD Billion)
  • 7.11. Others
    • 7.11.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 8. Type of Drug Business Analysis

  • 8.1. Active Pharmaceutical Ingredients Market: Type of Drug Movement Analysis
  • 8.2. Prescription
    • 8.2.1. Prescription Market, 2018 - 2030 (USD Billion)
      • 8.2.1.1. OTC
      • 8.2.1.2. OTC Market, 2018 - 2030 (USD Billion)

Chapter 9. Regional Business Analysis

  • 9.1. Active Pharmaceutical Ingredients Market Share By Region, 2023 & 2030
  • 9.2. North America
    • 9.2.1. North America Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.2.2. U.S.
      • 9.2.2.1. Key Country Dynamics
      • 9.2.2.2. Target Disease Prevalence
      • 9.2.2.3. Competitive Scenario
      • 9.2.2.4. Regulatory Framework
      • 9.2.2.5. Reimbursement Scenario
      • 9.2.2.6. U.S. Active pharmaceutical ingredients market, 2018 - 2030 (USD MILLION)
    • 9.2.3. Canada
      • 9.2.3.1. Key Country Dynamics
      • 9.2.3.2. Target Disease Prevalence
      • 9.2.3.3. Competitive Scenario
      • 9.2.3.4. Regulatory Framework
      • 9.2.3.5. Reimbursement Scenario
      • 9.2.3.6. Canada Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.3. Europe
    • 9.3.1. Europe Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.3.2. Germany
      • 9.3.2.1. Key Country Dynamics
      • 9.3.2.2. Target Disease Prevalence
      • 9.3.2.3. Competitive Scenario
      • 9.3.2.4. Regulatory Framework
      • 9.3.2.5. Reimbursement Scenario
      • 9.3.2.6. Germany Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.3.3. UK
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Target Disease Prevalence
      • 9.3.3.3. Competitive Scenario
      • 9.3.3.4. Regulatory Framework
      • 9.3.3.5. Reimbursement Scenario
      • 9.3.3.6. UK Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.3.4. France
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Target Disease Prevalence
      • 9.3.4.3. Competitive Scenario
      • 9.3.4.4. Regulatory Framework
      • 9.3.4.5. Reimbursement Scenario
      • 9.3.4.6. France Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.3.5. Italy
      • 9.3.5.1. Key Country Dynamics
      • 9.3.5.2. Target Disease Prevalence
      • 9.3.5.3. Competitive Scenario
      • 9.3.5.4. Regulatory Framework
      • 9.3.5.5. Reimbursement Scenario
      • 9.3.5.6. Italy Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.3.6. Spain
      • 9.3.6.1. Key Country Dynamics
      • 9.3.6.2. Target Disease Prevalence
      • 9.3.6.3. Competitive Scenario
      • 9.3.6.4. Regulatory Framework
      • 9.3.6.5. Reimbursement Scenario
      • 9.3.6.6. Spain Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.3.7. Denmark
      • 9.3.7.1. Key Country Dynamics
      • 9.3.7.2. Target Disease Prevalence
      • 9.3.7.3. Competitive Scenario
      • 9.3.7.4. Regulatory Framework
      • 9.3.7.5. Reimbursement Scenario
      • 9.3.7.6. Denmark Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.3.8. Sweden
      • 9.3.8.1. Key Country Dynamics
      • 9.3.8.2. Target Disease Prevalence
      • 9.3.8.3. Competitive Scenario
      • 9.3.8.4. Regulatory Framework
      • 9.3.8.5. Reimbursement Scenario
      • 9.3.8.6. Sweden Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.3.9. Norway
      • 9.3.9.1. Key Country Dynamics
      • 9.3.9.2. Target Disease Prevalence
      • 9.3.9.3. Competitive Scenario
      • 9.3.9.4. Regulatory Framework
      • 9.3.9.5. Reimbursement Scenario
      • 9.3.9.6. Norway Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.4.2. Japan
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Target Disease Prevalence
      • 9.4.2.3. Competitive Scenario
      • 9.4.2.4. Regulatory Framework
      • 9.4.2.5. Reimbursement Scenario
      • 9.4.2.6. Japan Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.4.3. China
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Target Disease Prevalence
      • 9.4.3.3. Competitive Scenario
      • 9.4.3.4. Regulatory Framework
      • 9.4.3.5. Reimbursement Scenario
      • 9.4.3.6. China Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.4.4. India
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Target Disease Prevalence
      • 9.4.4.3. Competitive Scenario
      • 9.4.4.4. Regulatory Framework
      • 9.4.4.5. Reimbursement Scenario
      • 9.4.4.6. India Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.4.5. South Korea
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Target Disease Prevalence
      • 9.4.5.3. Competitive Scenario
      • 9.4.5.4. Regulatory Framework
      • 9.4.5.5. Reimbursement Scenario
      • 9.4.5.6. South Korea Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.4.6. Australia
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Target Disease Prevalence
      • 9.4.6.3. Competitive Scenario
      • 9.4.6.4. Regulatory Framework
      • 9.4.6.5. Reimbursement Scenario
      • 9.4.6.6. Australia Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.4.7. Thailand
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Target Disease Prevalence
      • 9.4.7.3. Competitive Scenario
      • 9.4.7.4. Regulatory Framework
      • 9.4.7.5. Reimbursement Scenario
      • 9.4.7.6. Thailand Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.5. Latin America
    • 9.5.1. Latin America Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.5.2. Brazil
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Target Disease Prevalence
      • 9.5.2.3. Competitive Scenario
      • 9.5.2.4. Regulatory Framework
      • 9.5.2.5. Reimbursement Scenario
      • 9.5.2.6. Brazil Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.5.3. Mexico
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Target Disease Prevalence
      • 9.5.3.3. Competitive Scenario
      • 9.5.3.4. Regulatory Framework
      • 9.5.3.5. Reimbursement Scenario
      • 9.5.3.6. Mexico Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.5.4. Argentina
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Target Disease Prevalence
      • 9.5.4.3. Competitive Scenario
      • 9.5.4.4. Regulatory Framework
      • 9.5.4.5. Reimbursement Scenario
      • 9.5.4.6. Argentina Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.6. MEA
    • 9.6.1. MEA Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.6.2. South Africa
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Target Disease Prevalence
      • 9.6.2.3. Competitive Scenario
      • 9.6.2.4. Regulatory Framework
      • 9.6.2.5. Reimbursement Scenario
      • 9.6.2.6. South Africa Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Target Disease Prevalence
      • 9.6.3.3. Competitive Scenario
      • 9.6.3.4. Regulatory Framework
      • 9.6.3.5. Reimbursement Scenario
      • 9.6.3.6. Saudi Arabia Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.6.4. UAE
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Target Disease Prevalence
      • 9.6.4.3. Competitive Scenario
      • 9.6.4.4. Regulatory Framework
      • 9.6.4.5. Reimbursement Scenario
      • 9.6.4.6. UAE Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
    • 9.6.5. Kuwait
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Target Disease Prevalence
      • 9.6.5.3. Competitive Scenario
      • 9.6.5.4. Regulatory Framework
      • 9.6.5.5. Reimbursement Scenario
      • 9.6.5.6. Kuwait Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)

Chapter 10. Competitive Landscape

  • 10.1. Participant's overview
  • 10.2. Financial performance
  • 10.3. Participant categorization
    • 10.3.1. Market Leaders
    • 10.3.2. Active Pharmaceutical Ingredients Market Share Analysis, 2023
    • 10.3.3. Company Profiles
      • 10.3.3.1. Dr. Reddy's Laboratories Ltd.
      • 10.3.3.1.1. Company Overview
      • 10.3.3.1.2. Financial Performance
      • 10.3.3.1.3. Product Benchmarking
      • 10.3.3.1.4. Strategic Initiatives
      • 10.3.3.2. Sun Pharmaceutical Industries Ltd.
      • 10.3.3.2.1. Company Overview
      • 10.3.3.2.2. Financial Performance
      • 10.3.3.2.3. Product Benchmarking
      • 10.3.3.2.4. Strategic Initiatives
      • 10.3.3.3. Teva Pharmaceutical Industries Ltd.
      • 10.3.3.3.1. Company Overview
      • 10.3.3.3.2. Financial Performance
      • 10.3.3.3.3. Product Benchmarking
      • 10.3.3.3.4. Strategic Initiatives
      • 10.3.3.4. Cipla Inc.
      • 10.3.3.4.1. Company Overview
      • 10.3.3.4.2. Financial Performance
      • 10.3.3.4.3. Product Benchmarking
      • 10.3.3.4.4. Strategic Initiatives
      • 10.3.3.5. AbbVie Inc.
      • 10.3.3.5.1. Company Overview
      • 10.3.3.5.2. Financial Performance
      • 10.3.3.5.3. Product Benchmarking
      • 10.3.3.5.4. Strategic Initiatives
      • 10.3.3.6. Aurobindo Pharma
      • 10.3.3.6.1. Company Overview
      • 10.3.3.6.2. Financial Performance
      • 10.3.3.6.3. Product Benchmarking
      • 10.3.3.6.4. Strategic Initiatives
      • 10.3.3.7. Sandoz International GmbH (Novartis AG)
      • 10.3.3.7.1. Company Overview
      • 10.3.3.7.2. Financial Performance
      • 10.3.3.7.3. Product Benchmarking
      • 10.3.3.7.4. Strategic Initiatives
      • 10.3.3.8. Viatris Inc.
      • 10.3.3.8.1. Company Overview
      • 10.3.3.8.2. Financial Performance
      • 10.3.3.8.3. Product Benchmarking
      • 10.3.3.8.4. Strategic Initiatives
      • 10.3.3.9. Fresenius Kabi AG
      • 10.3.3.9.1. Company Overview
      • 10.3.3.9.2. Financial Performance
      • 10.3.3.9.3. Product Benchmarking
      • 10.3.3.9.4. Strategic Initiatives
      • 10.3.3.10. STADA Arzneimittel AG
      • 10.3.3.10.1. Company Overview
      • 10.3.3.10.2. Financial Performance
      • 10.3.3.10.3. Product Benchmarking
      • 10.3.3.10.4. Strategic Initiatives
    • 10.3.4. Strategy Mapping
      • 10.3.4.1. Expansion
      • 10.3.4.2. Acquisition
      • 10.3.4.3. Collaborations
      • 10.3.4.4. Disease Type/Drug Class Launch
      • 10.3.4.5. Partnerships
      • 10.3.4.6. Others